Landmark victory!
The FDA announced their approval of Krystal Biotech’s VYJUVEK™ for the treatment of Dystrophic Epidermolysis Bullosa (DEB). EB Research Partnership (“EBRP”) invested in Krystal Biotech by way of a private placement after Krystal’s Biotech’s initial public offering in 2017 using EBRP’s Venture Philanthropy model. This is not only the first-ever FDA approved treatment for those battling DEB, but also the first FDA approved topical, redosable gene therapy.
400 million people around the world are affected by a rare disease. 95% of rare diseases lack an FDA approved treatment or cure. Today, DEB warriors around the world cross into the 5% with the approval of Krystal Biotech’s VYJUVEK. VYJUVEK is a non-invasive, topical, redosable gene therapy.
A SCALABLE MODEL THAT’S BREAKING GROUND
This FDA approval marks a milestone in EBRP’s mission to discover treatments and a cure for EB. It provides validation for our scalable and sustainable Venture Philanthropy business model and most importantly creates hope for families around the world battling EB every day.
EBRP’s Venture Philanthropy business model has been highlighted for its leadership by Harvard Business School, Yale University, and MIT in helping to fast-track not only a cure for EB but therapies that could affect thousands of other rare diseases.
EBRP invested in Krystal Biotech in 2017, shortly after Krystal Biotech’s initial public offering of common stock. The investment was made via a private placement of Krystal Biotech’s common stock, and as part of the stock purchase agreement, Krystal Biotech committed to commence a Phase I clinical trial of VYJUVEK. The funding followed the highly competitive application and screening process overseen by EBRP’s Scientific Advisory Board (SAB), which is composed of leading scientists and physicians. EBRP was able to generate a more than double return on its investment and reinvest that capital back into more EB projects.
400 million people around the world are affected by a rare disease. 95% of rare diseases lack an FDA approved treatment or cure. Today, DEB warriors around the world cross into the 5% with the approval of Krystal Biotech’s VYJUVEK. VYJUVEK is a non-invasive, topical, redosable gene therapy.
A SCALABLE MODEL THAT’S BREAKING GROUND
This FDA approval marks a milestone in EBRP’s mission to discover treatments and a cure for EB. It provides validation for our scalable and sustainable Venture Philanthropy business model and most importantly creates hope for families around the world battling EB every day.
EBRP’s Venture Philanthropy business model has been highlighted for its leadership by Harvard Business School, Yale University, and MIT in helping to fast-track not only a cure for EB but therapies that could affect thousands of other rare diseases.
EBRP invested in Krystal Biotech in 2017, shortly after Krystal Biotech’s initial public offering of common stock. The investment was made via a private placement of Krystal Biotech’s common stock, and as part of the stock purchase agreement, Krystal Biotech committed to commence a Phase I clinical trial of VYJUVEK. The funding followed the highly competitive application and screening process overseen by EBRP’s Scientific Advisory Board (SAB), which is composed of leading scientists and physicians. EBRP was able to generate a more than double return on its investment and reinvest that capital back into more EB projects.
|
|
about eb research partnership
Our Mission
We're the largest global nonprofit funding research to discover treatments and cures for Epidermolysis Bullosa (EB), a group of rare and life-threatening genetic disorders that affect the body's largest organ - the skin. Children with EB lack proteins that bind the skin's two layers together, causing it to blister and shear off from even the slightest friction. To date, we've funded 120+ research projects, transforming the clinical landscape from just 2 clinical trials in EB when we were founded to 40 today.
Our Model
At EBRP, we pride ourselves on innovating to accelerate the path to a cure for EB. Through our Venture Philanthropy model, we negotiate a financial interest in the research we fund. If that research leads to a commercially successful therapy, we use our returns to fund additional EB research. In other words, your donation has the potential to grow to multiples of its original value.
We're the largest global nonprofit funding research to discover treatments and cures for Epidermolysis Bullosa (EB), a group of rare and life-threatening genetic disorders that affect the body's largest organ - the skin. Children with EB lack proteins that bind the skin's two layers together, causing it to blister and shear off from even the slightest friction. To date, we've funded 120+ research projects, transforming the clinical landscape from just 2 clinical trials in EB when we were founded to 40 today.
Our Model
At EBRP, we pride ourselves on innovating to accelerate the path to a cure for EB. Through our Venture Philanthropy model, we negotiate a financial interest in the research we fund. If that research leads to a commercially successful therapy, we use our returns to fund additional EB research. In other words, your donation has the potential to grow to multiples of its original value.
